Treatment of Very High-Risk NMIBC When BCG-Based Therapy Has Failed

Clinical scenario

This protocol addresses patients with non-muscle-invasive bladder cancer in the very high-risk group — defined by T1 HG/G3 with concurrent carcinoma in situ, T1 HG/G3 without CIS with all three additional risk factors (age over 70, multiple tumours, tumour diameter over 3 cm), certain high-grade Ta tumours with CIS and all risk factors, T1 G2 with CIS and at least two risk factors, or the presence of lymphovascular invasion or aggressive urothelial carcinoma subtypes — without CIS in the prostatic urethra. This group carries an extremely high risk of tumour progression.

Previous treatment and failure condition

BCG-based therapy did not achieve the required targets

The prior line — radical cystectomy (preferred for eligible patients) or transurethral resection of the bladder tumour followed by full-course intravesical BCG, optionally combined with systemic immunotherapy in selected BCG-naive patients — did not achieve:

No high-grade bladder tumour on cystoscopy at 3 months
No carcinoma in situ on bladder biopsy at 6 months
Negative urine cytology for high-grade urothelial carcinoma

BCG-unresponsive tumours are unlikely to respond to further BCG therapy. This protocol describes the next step.

Next-line approach (overview)

Radical cystectomy is the standard and preferred treatment for BCG-unresponsive disease. For patients who are not candidates for surgery or who decline it, bladder-preservation strategies — intravesical or systemic — are available, though these are considered oncologically inferior to surgery. Full regimen details, eligibility criteria, and sequencing are in the complete protocol.

Treatment goals

No bladder tumour on cystoscopy at 3 months
Complete response of carcinoma in situ on bladder biopsy
Negative urine cytology for high-grade urothelial carcinoma

Instant Access to Structured Evidence-Based Regimens

References

T1 HG/G3 and CIS with at least one risk factor.

T1 HG/G3 no CIS with all three risk factors.

Ta HG/G3 and CIS with all three risk factors.

T1 G2 and CIS with at least two risk factors.

All patients with CIS in the prostatic urethra, with certain subtypes of UC, or with LVI, should be included in the very high-risk group.

Patients in the very high-risk group have an extremely high risk of tumour progression.

Offer an RC to patients with BCG-unresponsive tumours.

Patients with BCG-unresponsive disease are unlikely to respond to further BCG therapy; RC is therefore the standard and preferred option.

Offer patients with BCG-unresponsive tumours, who are not candidates for RC due to comorbidities, or who decline RC, preservation strategies (intravesical chemotherapy, chemotherapy and microwave-induced hyperthermia, electromotive administration of chemotherapy, intravesical- or systemic immunotherapy; preferably within clinical trials).

Treatments other than RC must be considered oncologically inferior in patients with BCG-unresponsive tumours.

The first cystoscopy after TURBT at three months is an important prognostic indicator for recurrence and progression.

View source ↗